13004-42-7

Usage

Uses

Used in Pharmaceutical Industry:
7-HYDROXY-3-(4-METHOXYPHENYL)-2-METHYL-4H-CHROMEN-4-ONE is used as a potential drug candidate for the development of new therapeutic agents due to its antioxidant, anti-inflammatory, and anticancer properties.
Used in Diabetes Treatment:
In the healthcare industry, 7-HYDROXY-3-(4-METHOXYPHENYL)-2-METHYL-4H-CHROMEN-4-ONE is used as a potential therapeutic agent for diabetes treatment, as it has been studied for its effects on managing the disease.
Used in Neurodegenerative Disorders Treatment:
7-HYDROXY-3-(4-METHOXYPHENYL)-2-METHYL-4H-CHROMEN-4-ONE is used as a potential therapeutic agent for neurodegenerative disorders, given its potential to mitigate the effects of these conditions.
Used in Cardiovascular Diseases Treatment:
In the field of cardiology, 7-HYDROXY-3-(4-METHOXYPHENYL)-2-METHYL-4H-CHROMEN-4-ONE is used as a potential therapeutic agent for cardiovascular diseases, leveraging its biological activities to improve patient outcomes.

InChI:InChI=1/C17H14O4/c1-10-16(11-3-6-13(20-2)7-4-11)17(19)14-8-5-12(18)9-15(14)21-10/h3-9,18H,1-2H3

Upstream product

• 70460-66-1 7-acetoxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one 
• 487-49-0 1-(2,4-dihydroxyphenyl)-2-(4-methoxyphenyl)ethanone 
• 108-24-7 acetic anhydride 
• 104-01-8 4-Methoxyphenylacetic acid 
• 75-36-5 acetyl chloride 
• 127-19-5 N,N-dimethyl acetamide 
• 34544-85-9 4-methoxybenzyl-2,4-diacetoxyphenyl ketone 
• 108-46-3 recorcinol 
• 104-47-2 p-methoxybenzylnitrile 

Downstream Products

• 112553-24-9 7-allyloxy-3-(4-methoxy-phenyl)-2-methyl-chromen-4-one 
• 394237-61-7 4-(4-(4-methoxyphenyl)-5-methyl-1H-pyrazol-3-yl)benzene-1,3-diol 
• 6716-73-0 ethyl [3-(4-methoxyphenyl)-2-methyl-4-oxo-4H-chromen-7-yloxy]acetate 
• 747412-79-9 4-[4-(4-methoxyphenyl)-3-methyl-1.2-oxazol-5-yl]benzene-1,3-diol 
• 610762-26-0 2-methyl-7-[(2-methylprop-2-enyl)oxy]-3-(4-methoxyphenyl)-4H-chromen-4-one 
• 70894-40-5 7,4'-dimethoxy-2-methylisoflavone 
• 1400917-37-4 1-{[7-hydroxy-3-(4-methoxyphenyl)-2-methyl-4-oxo-4H-chromen-8-yl]methyl}-L-proline 
• 1400917-46-5 1-{[7-hydroxy-3-(4-methoxyphenyl)-2-methyl-4-oxo-4H-chromen-8-yl]methyl}piperidine-2-carboxylic acid 
• 1400917-47-6 1-{[7-hydroxy-3-(4-methoxyphenyl)-2-methyl-4-oxo-4H-chromen-8-yl]methyl}piperidine-3-carboxylic acid 
• 1400917-48-7 1-{[7-hydroxy-3-(4-methoxyphenyl)-2-methyl-4-oxo-4H-chromen-8-yl]methyl}piperidine-4-carboxylic acid 
• 879927-27-2 7-(2-bromoethoxy)-2-methyl-3-(4-methoxyphenyl)-4H-chromen-4-one 

Relevant academic research and scientific papers

Chemoselective synthesis of 3-trifluoromethylpyrazole-deoxybenzoin hybrids

A simple method of the synthesis of α-(3(5)-trifluoromethylpyrazol-5(3)-yl)-2-hydroxydeoxybenzoins by a chemoselective reaction of 2-(1,1,1-trifluoroacetonyl)chromones with hydrazine dihydrochloride was developed. This approach involves the initial attack of hydrazine at the carbonyl atom of the CF3C(O)CH2 group followed by the chromone ring opening at C-2 atom and subsequent cyclization to pyrazoles. Such synthetic strategy provides easy access to the novel type of pharmaceutically attractive 3-(trifluomethyl)pyrazole-deoxybenzoin hybrids in high yields.

Repurposing Hsp90 inhibitors as antibiotics targeting histidine kinases

To address the growing need for new antimicrobial agents, we explored whether inhibition of bacterial signaling machinery could inhibit bacterial growth. Because bacteria rely on two-component signaling systems to respond to environmental changes, and because these systems are both highly conserved and mediated by histidine kinases, inhibiting histidine kinases may provide broad spectrum antimicrobial activity. The histidine kinase ATP binding domain is conserved with the ATPase domain of eukaryotic Hsp90 molecular chaperones. To find a chemical scaffold for compounds that target histidine kinases, we leveraged this conservation. We screened ATP competitive Hsp90 inhibitors against CckA, an essential histidine kinase in Caulobacter crescentus that controls cell growth, and showed that the diaryl pyrazole is a promising scaffold for histidine kinase inhibition. We synthesized a panel of derivatives and found that they inhibit the histidine kinases C. crescentus CckA and Salmonella PhoQ but not C. crescentus DivJ; and they inhibit bacterial growth in both Gram-negative and Gram-positive bacterial strains.

Synthesis and tautomerization of hydroxylated isoflavones bearing heterocyclic hemi-aminals

The aminomethylation of hydroxylated isoflavones with 2-aminoethanol, 3-amino-1-propanol, 4-amino-1-butanol, and 5-amino-1-pentanol in the presence of excess formaldehyde led principally to 9-(2-hydroalkyl)-9,10-dihydro-4H,8H-chromeno[8,7-e][1,3]-oxazin-4-ones 4 and/or the tautomeric 7-hydroxy-8-(1,3-oxazepan-3-ylmethyl)-4H-chromen-4-ones 5. The ratio of these tautomers was dependent on solvent polarity, electronic effects of aryl substituents in the isoflavone and the structure of the amino alcohol. NMR studies confirmed the interconversion of tautomeric forms.

7-Hydroxy-benzopyran-4-one derivatives: A novel pharmacophore of peroxisome proliferator-activated receptor α and -γ (PPARα and γ) dual agonists

Design, synthesis, and in vitro bioevaluation of a new class of potential dual PPARα and γ agonists discovered through a structure-driven design paradigm are described. The 7-hydroxy-benzopyran-4-one moiety (includes flavones, flavanones, and isoflavones) is the key pharmacophore of these novel molecules, exhibiting similarity to the core structure of both fibrates and thiazolidinediones. New lead PPAR ligands were identified from "natraceuticals" and synthetic analogues. In total, 77 molecules, including chalcones, flavones, flavanones, isoflavones, and pyrazole derivatives, were screened and structure-activity relationship studies of the dual agonists undertaken. Compounds 68, 70, 72, and 76 were identified as novel and potent dual PPARα and γ agonists. These novel molecules may have the potential to be the future leads in PPAR-related disorders, including type II diabetes mellitus and metabolic syndrome. 2009 American Chemical Society.

Synthesis of 2-alkylisoflavones under phase-transfer catalysis conditions

2-alkyl isoflavones were synthesised with the aliphatic acid chloride and 2-hydroxydeoxybenzoins under phase-transfer catalysis in acetone-K 2CO3 medium involves the modified Baker-VenKataraman transformation.

Novel, potent small-molecule inhibitors of the molecular chaperone Hsp90 discovered through structure-based design

The crystal structure of a previously reported screening hit 1 (CCT018159) bound to the N terminal domain of molecular chaperone Hsp90 has been used to design 5-amide analogues. These exhibit enhanced potency against the target in binding and functional a

ISOXAZOLE COMPOUNDS AS INHIBITORS OF HEAT SHOCK PROTEINS

Isoxazoles of formula (A) or (B) are inhibitors of HSP90 activity, and useful for treatment of, for example cancers: (A), (B) wherein R1, is a group of formula (IA): -Ar1-(Alk1)p-(Z)r-(Alk2)S-Q, wherein in any compatible combination Ar1 is an optionally substituted aryl or heteroaryl radical, Alk1and Alk2 are optionally substituted divalent Cl-C6 alkylene or C2-C6 alkenylene radicals, p, r and s are independently 0 or 1, Z is -0-, -S-, -(C=O)-, -(C=S)-, -SO2-, -C(=O)O-, -C(=O)NRA-, -C(=S)NRA-, - SO2NRA-, -NRAC(=O)-, -NRASO2- or -NRA- wherein RA is hydrogen or Cl-C6 alkyl, and Q is hydrogen or an optionally substituted carbocyclic or heterocyclic radical; R2 is (i) a group of formula (IA) above or (ii) a carboxamide radical; or (iii) a non aromatic carbocyclic or heterocyclic ring wherein a ring carbon is optionally substituted, and/or a ring nitrogen is optionally substituted by a group of formula -(Alk1)p-(Z)r-(Alk2)s-Q wherein Q, Alk1, Alk2, Z, p, r and s are as defined above in relation to group (IA); and R3 is hydrogen, optionally substituted cycloalkyl, cycloalkenyl, C1-C6 alkyl, C1-C6 alkenyl, or C1-C6 alkynyl; or a carboxyl, carboxamide, or carboxyl ester group.